Advertisement

Avaxia Biologics Inc. has won a Phase 1 Small Business Innovation Research (SBIR) grant from the National Institutes of Health to develop a new antibody therapeutic for celiac disease that can be taken orally.

Wayland-based Avaxia received approximately $145,000 in research and development funds from the National Institute of Diabetes and Digestive and Kidney Diseases unit of the NIH. The company will apply its proprietary platform technology to the development of the antibody therapeutic, according to officials.

SOURCE

Advertisement
Advertisement